Mark Gilbert, MD, neuro-oncologist, chief of neuro-oncology, National Institute of Health, discusses predicting how a patient's brain tumor might act and respond to treatment based on their genetics.
Mark Gilbert, MD, neuro-oncologist, chief of neuro-oncology, National Institute of Health, discusses predicting how a patient's brain tumor might act and respond to treatment based on their genetics. Gilbert says one way an oncologist might be able to predict these factors is looking at a patient's nucleotides in their DNA. He says these polymorphisms can reveal different types of enzyme activity, which in turn can potentially allow oncologists to guess more accurately at how a treatment might impact a patient.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More